Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuit
INTU
|
+$358M |
| 2 |
Salesforce
CRM
|
+$251M |
| 3 |
Alibaba
BABA
|
+$173M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$159M |
| 5 |
S&P Global
SPGI
|
+$119M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$497M |
| 2 |
TWTR
Twitter, Inc.
TWTR
|
+$340M |
| 3 |
ZEN
ZENDESK INC
ZEN
|
+$296M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$294M |
| 5 |
Meta Platforms (Facebook)
META
|
+$245M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 32.5% |
| 2 | Technology | 18.76% |
| 3 | Financials | 14.5% |
| 4 | Industrials | 8.38% |
| 5 | Communication Services | 4.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Visa
V
$693B
| $259M | 1.53% |
1,249,010
-263,200
| -17% | -$53.1M |
|
27
Blackstone
BX
$108B
| $241M | 1.42% |
3,248,951
+134,000
| +4% | +$11.6M |
|
28
Aon
AON
$75.3B
| $237M | 1.4% |
788,086
-20,400
| -3% | -$5.96M |
|
|
29
Alibaba
BABA
$286B
| $234M | 1.38% |
2,661,000
+2,197,000
| +473% | +$173M |
|
|
XYZ
30
Block Inc
XYZ
$49.4B
| $202M | 1.19% |
3,218,000
+634,000
| +25% | +$39.1M |
|
31
New York Times
NYT
$10.6B
| $197M | 1.16% |
6,068,791
-1,759,282
| -22% | -$57.3M |
|
32
United Therapeutics
UTHR
$22B
| $182M | 1.08% |
655,873
+106,200
| +19% | +$26.8M |
|
33
CoStar Group
CSGP
$13.1B
| $176M | 1.04% |
2,280,185
-680,000
| -23% | -$53.1M |
|
34
Exelixis
EXEL
$13.4B
| $174M | 1.03% |
10,868,149
+192,305
| +2% | +$3.14M |
|
|
VMW
35
DELISTED
VMware, Inc
VMW
| $171M | 1.01% |
1,390,623
+215,000
| +18% | +$24.8M |
|
36
Biogen
BIIB
$32B
| $164M | 0.97% |
592,699
+287,200
| +94% | +$81.1M |
|
37
AbbVie
ABBV
$468B
| $152M | 0.9% |
939,212
+214,100
| +30% | +$32.8M |
|
38
Humana
HUM
$45.5B
| $138M | 0.82% |
270,400
+19,200
| +8% | +$10.1M |
|
39
Beam Therapeutics
BEAM
$3.07B
| $133M | 0.79% |
3,399,921
-231,350
| -6% | -$10.4M |
|
40
Clarivate
CLVT
$1.33B
| $127M | 0.75% |
15,177,433
-25,368,867
| -63% | -$238M |
|
41
Sarepta Therapeutics
SRPT
$1.98B
| $120M | 0.71% |
928,900
+173,950
| +23% | +$20.2M |
|
|
SGFY
42
DELISTED
Signify Health, Inc.
SGFY
| $113M | 0.67% |
3,950,000
+3,600,000
| +1,029% | +$104M |
|
|
MASI
43
DELISTED
Masimo
MASI
| $112M | 0.66% |
758,500
+181,500
| +31% | +$25M |
|
|
LHCG
44
DELISTED
LHC Group LLC
LHCG
| $111M | 0.66% |
689,000
+39,000
| +6% | +$6.44M |
|
45
PG&E
PCG
$38.8B
| $83.8M | 0.5% |
5,155,142
-1,150,000
| -18% | -$17.4M |
|
46
KE Holdings
BEKE
$19.6B
| $80.4M | 0.47% |
5,758,500
-4,200,000
| -42% | -$58.4M |
|
|
ONEM
47
DELISTED
1Life Healthcare
ONEM
| $79M | 0.47% |
4,725,000
+1,800,000
| +62% | +$30.4M |
|
48
Cytokinetics
CYTK
$10.7B
| $78M | 0.46% |
1,701,738
+80,700
| +5% | +$3.47M |
|
49
Lufax Holding
LU
$1.2B
| $74.6M | 0.44% |
9,609,100
+4,475,000
| +87% | +$34.1M |
|
50
Enanta Pharmaceuticals
ENTA
$392M
| $72.1M | 0.43% |
1,550,000
| – | – |
|
Similar funds
Thomas Steyer's Q4 2022 Portfolio in Review
As of Q4 2022, Thomas Steyer held 323 positions worth $16.9B, down 7% from $18.2B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Thomas Steyer withdrew a net $3.58B in Q4 2022, closing 80 positions and reducing 39 holdings. Its most notable exit was Change Healthcare Inc. Common Stock, an estimated $497M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 28% a quarter earlier, followed by Technology and Financials.
Against the trend, Thomas Steyer opened a new position in Intuit worth $351M.
- Thomas Steyer's largest Q4 2022 buy was Intuit: 902,100 shares worth $351M.
- Thomas Steyer added most to Salesforce in Q4 2022, an estimated $251M increase.
- Thomas Steyer's biggest Q4 2022 reduction was Clarivate, cutting an estimated $238M.
- Thomas Steyer fully exited Change Healthcare Inc. Common Stock in Q4 2022, selling an estimated $497M.
- Thomas Steyer's ten largest holdings make up 35% of its $16.9B portfolio in Q4 2022.
- Thomas Steyer opened 13 new positions and closed 80 in Q4 2022.
- Thomas Steyer's portfolio value fell 7% quarter-over-quarter to $16.9B.
Based on Farallon Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.